NEW YORK, SAN FRANCISCO & CARLSBAD, Calif.–(BUSINESS WIRE)–Biotech Showcase, the investor conference driving therapeutic innovation, advances in digital medicine, and broad industry collaboration, had more than 3,800 attendees, marking rising participation every year since the first meeting 12 years ago. This year’s Biotech Showcase took place in the third week of January and was produced by Demy-Colton and EBD Group.
“We’re thrilled to share that we’ve had another record year of investor attendance, company presentations, and partnering meetings at Biotech Showcase,” said Sara Jane Demy, founder and CEO, Demy-Colton. “For many in the biotech and healthcare space, this is one of the most important business weeks during their calendar year, where companies can have multiple meetings with serious investors and potential collaborators all in one place. We are proud to produce an event that is welcoming, unique and provides a highly valuable opportunity for today’s innovative biotechnology companies to connect and share their therapeutic advances with the larger community.”
“This year, Biotech Showcase attracted over 400 presenting companies and more than 1,000 investors, resulting in a remarkable level of engagement. Our plenary sessions and workshops were extremely popular and focused on some of the industry’s biggest challenges,” said Tina Gunnink, Managing Director, EBD Group US. “As we move into the new decade, it will be exciting to see how the investments and partnerships initiated at Biotech Showcase evolve and affect the healthcare landscape.”
Biotech Showcase’s robust program featured panels highlighting advancements in women’s health and rare disease, as well as discussions on drug pricing and the potential impact of the upcoming election. This year’s concurrent events, Digital Medicine & Medtech Showcase and China Showcase, also saw record attendees, and included panels on the impact of artificial intelligence and the international investment and partnering landscape.
The date for next year’s Biotech Showcase has been set for January 11–13, 2021 in San Francisco. For more information, please visit www.biotechshowcase.com or follow us on Twitter at @Demy_Colton and @EBDGroup.
Since 2008, Demy-Colton has been at the forefront of building networks between leaders from innovative biotech companies and industry stakeholders to examine and address biotech opportunities and challenges to help deliver on the promise of transformational developments in healthcare and technology.
Demy-Colton achieves this with unique meeting platforms that facilitate networking by the biotech community on an international scale. Its investor conferences and CEO Summits build networking communities that transcend geographical boundaries and establish ongoing, high-value relationships among the industry’s top decision makers, investors, and thought leaders. By setting a unique stage where investment, learning, and growth thrive, Demy-Colton’s events spur introductions and thoughtful conversations. In turn, inspiration, ideas, and opportunities for investment flow.
Demy-Colton’s specialized events and conferences include Biotech CEO Summit Europe, Biotech CEO Summit Napa, BioFuture™, Biotech Showcase™, China Showcase, and Digital Medicine & Medtech Showcase.
For more information on Demy-Colton, please visit www.demy-colton.com.
About EBD Group
EBD Group’s overriding mission is to help collaborations get started across the life science value chain. Our range of partnering conferences has grown to become the largest and most productive conference platform in the industry. Each one of our landmark events held in key life science markets around the world is powered by our state-of-the-art partnering software, partneringONE®, that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings.
Today our events (BIO-Europe®, BIO-Europe Spring®, BioPharm America™, Biotech Showcase™, China Showcase, Digital Medicine & Medtech Showcase, ChinaBio® Partnering Forum, Rare Disease Innovation and Partnering Summit, and BioEquity Europe) annually attract more than 15,000 senior life science executives who engage in over 50,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry.
EBD Group is an Informa company. For more information please visit www.ebdgroup.com.